
What is claimed is:

1. Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine in the manufacture of a medicament for treating advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV)

or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;

R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;


R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.

2. The use of claim 1, wherein a TOR kinase inhibitor is to be used in combination with an effective amount of erlotinib.

3. The use of claim 1, wherein a TOR kinase inhibitor is to be used in combination with an effective amount of azacitidine.

4. The use of claim 3, wherein the azacitidine is oral azacitidine.

5. Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine in the manufacture of a medicament for achieving a Response Evaluation Criteria in Solid Tumors (RECIST 1.1) of complete response, partial response or stable disease in a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV)

or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;

R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;


R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.

6. The use of claim 5, wherein a TOR kinase inhibitor is to be used in combination with an effective amount of erlotinib.

7. The use of claim 5, wherein a TOR kinase inhibitor is to be used in combination with an effective amount of azacitidine.

8. The use of claim 7, wherein the azacitidine is oral azacitidine.

9. Use of a TOR kinase inhibitor in combination with an effective amount of erlotinib or azacitidine in the manufacture of a medicament for increasing survival without tumor progression of a patient having advanced non-small cell lung cancer, wherein the TOR kinase inhibitor has the following formula (IV):



(IV)

or a pharmaceutically acceptable salt, clathrate, solvate, stereoisomer, tautomer, or prodrug thereof, wherein:

R^1 is substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted aryl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;

R^2 is H, substituted or unsubstituted C_{1-8} alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted aralkyl, or substituted or unsubstituted cycloalkylalkyl;

R^3 is H, or a substituted or unsubstituted C_{1-8} alkyl.

10. The use of claim 9, wherein a TOR kinase inhibitor is to be used in combination with an effective amount of erlotinib.

11. The use of claim 9, wherein a TOR kinase inhibitor is to be used in combination with an effective amount of azacitidine.